Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue

About this update from Tevogen Bio Holdings Inc.

Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue WARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced continued progress across its strategic acquisition initiatives intended to complement its existing business and support long-term financial self-sufficiency, which, if consummated, could realize approximately $100 million in combined annual revenue. These initiatives include the Company’s previously announced evaluation of a contract research organization (“CRO”), along with additional strategic acquisition opportunities aligned with Tevogen’s broader healthcare platform. Tevogen believes these and other strategic acquisition initiatives could support the Company’s evolution into a revenue-generating healthcare enterprise comprised of Tevogen Bio, its biotechnology arm; Tevogen.AI, its technology arm; and, subject to completion of proposed transactions, a healthcare services arm that may include management services and contract research operations. “Capital discipline and preserving the integrity of our capital structure are core priorities for us,” said Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio. “Our strategic objective is to build a financially self-sufficient healthcare enterprise with the financial strength to support operations, advance growth initiatives, and create long-term value through revenue generation. The acquisition opportunities we are evaluating represent an initial phase of that strategy, and any related capital allocation decisions will continue to be guided by strategic fit, long-term value creation, and disciplined stewardship of Tevogen’s capital structure.” The proposed transactions remain subject to, among other things, completion of due diligence, negotiation and execution of definitive documentation, required approvals, and satisfaction of customary closing conditions. There can be no assurance that any such transaction will be consummated. About Tevogen Tevogen is a socially integrated healthcare enterprise built on the principles of affordability, efficiency, and scientific rigor. The company leverages artificial intelligence and precision T cell therapy platforms, a patient-first and cost-disciplined operating model, and engagements with global technology leade...

View stock analysis, news, and events for Tevogen Bio Holdings Inc.